SUCLG2P2 and colonic neoplasm: When the expression of SUCLG2P2 decreases in colon cancer, the combined hsa-miR-588 decreases, which increases the binding of hsa-miR-588 to SUCLG2, which in turn leads to an increase in SUCLG2 degradation and a decrease in SUCLG2 expression.